Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia.

BACKGROUND Schizotypal personality disorder (SPD) shares social deficits and cognitive impairment with schizophrenia, but is not typically characterized by frank psychosis. Because striatal size and functional activity have both been shown to be associated with psychotic symptoms, we carried out the first study of SPD to assess the caudate and putamen for comparison with findings in schizophrenia. METHODS Patients with SPD (n = 16), schizophrenic patients (n = 42), and age- and sex-matched normal control subjects (n = 47) were assessed with magnetic resonance imaging. All of the patients with SPD and subsamples of the schizophrenic patients (n = 27) and control subjects (n = 32) were also assessed with positron emission tomography using fluorodeoxyglucose F-18. RESULTS The relative size of the putamen in controls was significantly larger than in patients with SPD and significantly smaller than in schizophrenic patients, while the relative size of the caudate was similar in all 3 groups. Compared with control values, relative glucose metabolic rate in the ventral putamen was significantly elevated in patients with SPD and reduced in schizophrenic patients. When subsamples of schizophrenic patients (n = 10) and patients with SPD (n = 10) both of whom never received medication were compared, this pattern was more marked, with the highest value for the putamen being found in patients with SPD for the ventral slice and the lowest value for the right dorsal putamen. CONCLUSIONS Patients with SPD showed reduced volume and elevated relative glucose metabolic rate of the putamen compared with both schizophrenic patients and controls. These alterations in volume and activity may be related to the sparing of patients with SPD from frank psychosis.

[1]  D. Delis,et al.  The California verbal learning test , 2016 .

[2]  R. McCarley.  MRI anatomy of schizophrenia: A review and update , 2001, European Neuropsychopharmacology.

[3]  J. Soares,et al.  Neurochemical brain imaging investigations of schizophrenia , 1999, Biological Psychiatry.

[4]  N C Andreasen,et al.  Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. , 1999, The American journal of psychiatry.

[5]  Ron Kikinis,et al.  Schizotypal personality disorder and MRI abnormalities of temporal lobe gray matter , 1999, Biological Psychiatry.

[6]  J. Joyce,et al.  D3 Receptors and the Actions of Neuroleptics in the Ventral Striatopallidal System of Schizophrenics , 1999, Annals of the New York Academy of Sciences.

[7]  R. McCarley,et al.  MRI anatomy of schizophrenia , 1999, Biological Psychiatry.

[8]  I. Creese,et al.  Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. , 1999, Life Science.

[9]  E. Perry,et al.  Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine , 1999, Neuroscience.

[10]  Cheuk Y. Tang,et al.  A method of basal forebrain anatomical standardization for functional image analysis , 1998, Psychiatry Research: Neuroimaging.

[11]  R. Gur,et al.  Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. , 1998, The American journal of psychiatry.

[12]  K. Krishnan,et al.  Magnetic-resonance morphometry in patients with major depression , 1998, Psychiatry Research: Neuroimaging.

[13]  J. Lieberman,et al.  Striatal enlargement in rats chronically treated with neuroleptic , 1998, Biological Psychiatry.

[14]  Philip D. Harvey,et al.  Age-related shift in brain region activity during successful memory performance , 1998, Neurobiology of Aging.

[15]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[16]  Philip D. Harvey,et al.  Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. , 1998, Archives of general psychiatry.

[17]  L. Mello,et al.  Neuroanatomy of the basal ganglia. , 1997, The Psychiatric clinics of North America.

[18]  Monte S. Buchsbaum,et al.  Ventricular volume and asymmetry in schizotypal personality disorder and schizophrenia assessed with magnetic resonance imaging , 1997, Schizophrenia Research.

[19]  H. Sauer,et al.  Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia: an [123I]iodobenzamide single photon emission computed tomography study , 1997, Psychiatry Research: Neuroimaging.

[20]  V S Caviness,et al.  Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients: a pilot magnetic resonance imaging study. , 1997, American journal of medical genetics.

[21]  J. Meador-Woodruff,et al.  Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia , 1997, Neuropsychopharmacology.

[22]  C. Adams,et al.  D1 and D2Dopamine Receptors in Perinatal and Adult Basal Ganglia , 1997, Pediatric Research.

[23]  D J Brooks,et al.  Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. , 1996, Brain : a journal of neurology.

[24]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Siever,et al.  D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder , 1996, Schizophrenia Research.

[26]  M. Buchsbaum.  Neuroimaging, VII: PET and the averaging of brain images. , 1996, The American journal of psychiatry.

[27]  Larry J. Siever,et al.  Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder , 1995, Psychiatry Research.

[28]  Cynthia G. Wible,et al.  Caudate, putamen, and globus pallidus volume in schizophrenia: A quantitative MRI study , 1995, Psychiatry Research: Neuroimaging.

[29]  M. Keshavan,et al.  Changes in caudate volume with neuroleptic treatment , 1994, The Lancet.

[30]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[31]  L. Siever,et al.  Eye movement impairment and schizotypal psychopathology. , 1994, The American journal of psychiatry.

[32]  L. Siever,et al.  The boundaries of schizophrenia. , 1993, The Psychiatric clinics of North America.

[33]  N C Andreasen,et al.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. , 1992, Archives of general psychiatry.

[34]  L. Siever,et al.  Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. , 1990, Archives of general psychiatry.

[35]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[36]  D L Braff,et al.  Sensorimotor gating and schizophrenia. Human and animal model studies. , 1990, Archives of general psychiatry.

[37]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[38]  M. Zimmerman,et al.  A structured interview for the DSM-III personality disorders. A preliminary report. , 1985, Archives of general psychiatry.

[39]  L L Iversen,et al.  Increased brain dopamine and dopamine receptors in schizophrenia. , 1982, Archives of general psychiatry.

[40]  J. Endicott,et al.  A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.

[41]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[42]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[43]  Philip D. Harvey,et al.  Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder , 2000, Neuropsychopharmacology.

[44]  N. Volkow,et al.  Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. , 2000, The American journal of psychiatry.

[45]  M. Buchsbaum,et al.  Positron Emission Tomography Studies of Abnormal Glucose Metabolism in Schizophrenia Circuitry and Fronto'striatal'thalamic Dysfunction Regional Cerebral Blood Flow (rcbf) Studies of Schizo- Phrenia by Ingvar and Franze'n (1974) Found a Relative , 2022 .

[46]  L. Siever,et al.  Plasma homovanillic acid in schizotypal personality disorder. , 1991, The American journal of psychiatry.

[47]  I. Creese,et al.  Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia. , 1986, Clinical neuropharmacology.

[48]  A. Hirano,et al.  AN ATLAS OF THE HUMAN BRAIN FOR COMPUTERIZED TOMOGRAPHY. , 1978 .

[49]  J. A. Subach,et al.  Significance Probability Mappings and Automated Interpretation of Complex Pictorial Scenes , 1976 .